Eisai has linked up with the USA’s Johns Hopkins University to develop new treatments in the area of neurology.
Under the terms of the agreement, Eisai will be provided with novel neurological drug discovery targets that have been discovered by scientists at the Johns Hopkins Brain Science Institute. In return, the latter will be given access to the Japanese drugmaker’s library of chemical compounds “as both parties seek to create clinically viable compounds”.
No financial details have been disclosed but Eisai will provide John Hopkins with upfront and milestone payments as well as royalties on future sales for each compound. The Tokyo-headquartered firm noted that it sees neurology “as a therapeutic area of focus” and the partnership with John Hopkins is “part of its commitment to uncovering the causes of disease”.
In May, Eisai expanded its 22-year collaboration with the UK’s University College London (UCL) which will see them engage in joint research in the neurodegenerative disease arena including biomarkers and drugs related to neuroinflammation, neurovascular/mitochondria, and proteostasis.
